Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07547228Phase 1Recruiting

A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)

Role: lead

NCT07541001Phase 2Active Not Recruiting

PRL3-Zumab in Patients With Advanced Solid Tumors

Role: lead

NCT04452955Phase 2Active Not Recruiting

A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors

Role: lead

NCT07290088Phase 2Recruiting

Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients

Role: lead

All 4 trials loaded